Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

27.62 -0.27 (-0.95%)
Streaming Delayed Price Updated: 12:41 PM EST, Nov 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Biotherapeutics Reveals Promising Data From Lead Drug In Pediatric Patients With Atopic Dermatitis ↗
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) announced that the INTEGUMENT-PED Phase 3 trial of roflumilast cream 0.05%, in children ages 2 to 5 years with mild to moderate atopic dermatitis met its... 
Via Benzinga
News headline image
Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Why Shares of Arcutis Biotherapeutics Fell This Week ↗
The company released phase 3 trial results for an atopic dermatitis cream. 
Via The Motley Fool
News headline image
7 Analysts Have This to Say About Arcutis Biotherapeutics ↗
 
Via Benzinga
News headline image
Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
US Stocks Mostly Higher; RH Posts Upbeat Earnings ↗
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 60 points on Friday. Following the market opening Friday, the Dow traded down 0.03% to 34,491.98 while the NASDAQ... 
Via Benzinga
Topics Stocks
News headline image
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
8 Analysts Have This to Say About Arcutis Biotherapeutics ↗
 
Via Benzinga
News headline image
Analyst Ratings for Arcutis Biotherapeutics ↗
 
Via Benzinga
News headline image
Arcutis to Present at Upcoming Investor Conference
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
3 Biotech Stocks Due for a Massive Short Squeeze ↗
These are the biotech short squeeze candidates to buy and hold for a massive rally of up to 100% in the coming quarters. 
Via InvestorPlace
News headline image
Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Analyst Expectations for Arcutis Biotherapeutics's Future ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Arcutis Biotherapeutics ↗
 
Via Benzinga
News headline image
Why Super League Gaming Are Trading Lower By Around 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) shares jumped 120% to $0.33. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Week In Review: Hengrui Out-Licenses Novel Anti-Inflammatory To One Bio In $1 Billion Deal ↗
Jiangsu Hengrui Pharma out-licensed global rights (ex-China) for a novel anti-inflammatory to One Bio of Florida in a $1 billion deal. One Bio will make an $21.5 million payment upfront along with a... 
Via Talk Markets
News headline image
Arcutis Appoints Interim Chief Financial Officer (CFO)
Former and First Arcutis CFO, John Smither, Appointed Interim 
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis to Report Second Quarter Financial Results
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Why Shares of Arcutis Biotherapeutics Jumped This Week ↗
The stock got a push when a British medical journal posted trials information on the company's lead product. 
Via The Motley Fool
News headline image
Arcutis to Present at Upcoming Investor Conference
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
7 Short-Interest Stocks to Target for Explosive Gains ↗
For contrarian investors that can stand the heat, short-interest stocks to buy can offer significant rewards in a short time period. 
Via InvestorPlace
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.